Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NBI 921352

Next Previous
Drug Profile

NBI 921352

Alternative Names: NBI-921352; XEN 901

Latest Information Update: 12 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenon Pharmaceuticals
  • Developer Neurocrine Biosciences; Xenon Pharmaceuticals
  • Class Antiepileptic drugs; Small molecules
  • Mechanism of Action Nav1.6 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy
  • Discontinued Dravet syndrome; Seizures

Most Recent Events

  • 27 May 2026 Neurocrine Biosciences terminates a phase II trial for Epilepsy (Adjunctive treatment, In children, In adolescents, In adults) in USA, Spain, Czech Republic, Poland, Portugal, Netherlands, Germany, Italy, France, Belgium, Denmark (PO) due to sponsor decision (EudraCT2021-004393-62) (NCT05226780)
  • 31 Dec 2024 Patent issued for NBI 921352 in Foreign jurisdictions
  • 31 Dec 2024 US FDA issued patent for NBI 921352

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top